January 28, 2020 06:43 AM ESTUpdated 09:08 AM

J&J's Spravato gets no love from NICE, jeopardizing its prospects in the UK

Natalie Grover

Reporter

UK’s cost-effectiveness watchdog NICE is taking the same track laid out by ICER — J&J’s pharmaceutical version of the hallucinogenic anesthetic ketamine, Spravato, is low …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J's Spravato gets no love from NICE, jeopardizing its prospects in the UK

Natalie Grover

Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Nvidia-backed Achira debuts, blending AI and physics to model molecules

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

J&J's Spra­va­to gets no love from NICE, jeop­ar­diz­ing its prospects in the UK

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

J&J's Spravato gets no love from NICE, jeopardizing its prospects in the UK